Stig K. Hansen

Stig Hansen is co-founder of Carmot Therapeutics and has served as Chief Executive Officer since the company’s inception. Dr. Hansen is the inventor of Chemotype Evolution, and he founded Carmot with a vision to transform drug discovery by industrializing Chemotype Evolution and applying it to high-impact therapeutic targets. In addition to his role a CEO, Dr. Hansen oversees technology innovation and early discovery. Prior to Carmot, Dr. Hansen was director of biology at Sunesis Pharmaceuticals, where he invented Chemotype Evolution and led drug discovery programs in metabolic disease, auto-immunity, and oncology, advancing two programs into clinical development. Dr. Hansen holds an MS in biochemistry and a Ph.D. in molecular and cell biology from the University of Copenhagen, Denmark. He conducted his Ph.D. studies in the laboratory of Dr. Robert Tjian at UC Berkeley, where he went on to become a Novartis Fellow of the Life Sciences Research Foundation studying mammalian brain development as a post-doctoral fellow.